Clinical trials: Sarcoidosis Associated Pulmonary Hypertension
Pulmonary Hypertension
Tadalafil for Sarcoidosis Associated Pulmonary Hypertension
This study is designed to assess safety and efficacy of tadalafil in patients with Sarcoidosis Associated Pulmonary Hypertension.
- Trial name
- SAPH (NCT01324999)
- Testing
- Tadalafil
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of North Carolina, Chapel Hill
Sarcoidosis, Pulmonary Arterial Hypertension
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
This trial will study the treatment of sarcoidosis-associated pulmonary arterial hypertension with inhaled iloprost, a drug approved for primary pulmonary arterial hypertension.
- Trial name
- NCT00403650
- Testing
- Iloprost
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
SARCOIDOSIS
Sarcoidosis-associated Pulmonary Hypertension
This prospective study was conducted to explore clinical characteristics and outcomes of patients diagnosed with pulmonary sarcoidosis and PH. The investigators also assessed the role of D -dimer levels in these population.
- Trial name
- NCT01139710
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Meir Medical Center
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
- Trial name
- NCT02036970
- Testing
- Bardoxolone methyl
- Where
- 32 sites in United States, Germany
- Volunteers
- 166 people
- Sponsor
- Biogen
Sarcoidosis, Pulmonary Arterial Hypertension
Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension
Patients with advanced sarcoidosis often develop pulmonary hypertension. Pulmonary hypertension is a condition where the right side of the heart has to push the blood though the lungs at a higher pressure than normal.
- Trial name
- BOSAPAH (NCT00581607)
- Testing
- Bosentan
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Cincinnati
Sarcoidosis-associated Pulmonary Hypertension
A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
Oral selexipag is commercially available in several countries for the treatment of a particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH).
- Trial name
- SPHINX (NCT03942211)
- Testing
- Selexipag
- Where
- 38 sites in United States, Belgium and 8 more
- Volunteers
- 10 people
- Sponsor
- Actelion
Pulmonary Hypertension, Pulmonary Fibrosis
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
A phase 2b, open label study to assess the safety and efficacy of increasing doses of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis and sarcoidosis on long term oxygen therapy followed by a long term…
- Conditions
- Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
- Trial name
- NCT03727451
- Testing
- iNO
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bellerophon
Sarcoidosis, Pulmonary Hypertension
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Hypothesis: Ambrisentan (Letairis ®) is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis
- Trial name
- NCT00851929
- Testing
- Ambrisentan
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Medical University of South Carolina
Sarcoidosis
Riociguat for Sarcoidosis Associated Pulmonary Hypertension
Double blind placebo controlled trial of riociguat for sarcoidosis associated pulmonary hypertension
- Trial name
- RioSAPH (NCT02625558)
- Testing
- Riociguat
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Cincinnati
Sarcoidosis, Pulmonary Hypertension
Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)
Registry to follow patients with sarcoidosis associated pulmonary hypertension
- Trial name
- RESAPH (NCT01467791)
- Testing
- Observation
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Cincinnati
Sarcoidosis Associated Pulmonary Hypertension
LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 (Inhaled Sirolimus) in Adults with Sarcoidosis Associated Pulmonary Hypertension (SAPH)
- Trial name
- NCT07886554
- Testing
- LAM-001
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- IRulya Therapeutics Inc.